GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » EV-to-EBITDA

Lavipharm (ATH:LAVI) EV-to-EBITDA : 17.57 (As of Jun. 16, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lavipharm's enterprise value is €173.34 Mil. Lavipharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €9.87 Mil. Therefore, Lavipharm's EV-to-EBITDA for today is 17.57.

The historical rank and industry rank for Lavipharm's EV-to-EBITDA or its related term are showing as below:

ATH:LAVI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.7   Med: 8.54   Max: 19.12
Current: 17.57

During the past 7 years, the highest EV-to-EBITDA of Lavipharm was 19.12. The lowest was 2.70. And the median was 8.54.

ATH:LAVI's EV-to-EBITDA is ranked worse than
61.32% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.44 vs ATH:LAVI: 17.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-16), Lavipharm's stock price is €0.89. Lavipharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.008. Therefore, Lavipharm's PE Ratio for today is 111.25.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Lavipharm EV-to-EBITDA Historical Data

The historical data trend for Lavipharm's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm EV-to-EBITDA Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial 9.17 8.98 10.47 14.87 15.97

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.47 - 14.87 - 15.97

Competitive Comparison of Lavipharm's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lavipharm's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lavipharm's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lavipharm's EV-to-EBITDA falls into.



Lavipharm EV-to-EBITDA Calculation

Lavipharm's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=173.338/9.867
=17.57

Lavipharm's current Enterprise Value is €173.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €9.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lavipharm  (ATH:LAVI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lavipharm's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.89/0.008
=111.25

Lavipharm's share price for today is €0.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Lavipharm EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lavipharm's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lavipharm (ATH:LAVI) Business Description

Traded in Other Exchanges
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm (ATH:LAVI) Headlines

No Headlines